Evidence map›Paper›PMID 26010599›Full record

ArticleJournal of biopharmaceutical statistics2016

Median-based incremental cost-effectiveness ratios with censored data.

Heejung Bang, Hongwei Zhao

Abstract read
In one paragraph

Article in Journal of biopharmaceutical statistics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Is [Cancers · 2025
    Review
  2. Cost-effectiveness of 2-[Scientific reports · 2023
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Heejung Banga Division of Biostatistics, Department of Public Health Sciences , University of California , Davis , California , USA.
Hongwei Zhaob Department of Epidemiology and Biostatistics , School of Public Health, Texas A&M Health Science Center, College Station , Texas , USA.

Funding

UC Davis Clinical and Translational Science CenterUL1TR000002 · NCATS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI BERGLUND, LARS F · 2012 to 2015
$12.2M
A Unified Approach of Cost-Effectiveness AnalysisR01HL096575 · NHLBI · WEILL MEDICAL COLL OF CORNELL UNIV · PI BANG, HEEJUNG · 2009 to 2011
$534k
NCATS NIH HHS UL1 TR000002NHLBI NIH HHS R01 HL096575
6 · The paper itself

Abstract

Cost-effectiveness is an essential part of treatment evaluation, in addition to effectiveness. In the cost-effectiveness analysis, a measure called the incremental cost-effectiveness ratio (ICER) is widely utilized, and the mean cost and the mean (quality-adjusted) life years have served as norms to summarize cost and effectiveness for a study population. Recently, the median-based ICER was proposed for complementary or sensitivity analysis purposes. In this article, we extend this method when some data are censored.

Indexed as

Cost-Benefit AnalysisHealth Care CostsData Interpretation, StatisticalHumansQuality-Adjusted Life YearsCensoringcost-effectiveness analysisICERmedian

Identifiers

PMID26010599
PMCPMC4816674

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.